Minerva Neurosciences, Inc. insider trading
Every open-market purchase and sale by Minerva Neurosciences, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Does following Minerva Neurosciences, Inc.’s insiders pay?
From January 8, 2015 to May 2, 2023, 17 insiders reported 17 open-market purchases and 32 sales not made under a pre-set plan in Minerva Neurosciences, Inc. Twelve months after each purchase was reported, the shares were −26.8% against the S&P 500 on average (median −30.2%), over 16 purchases with a full year of prices; 19% beat the index. After sales, the shares moved −24.7% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on March 18, 2015 into $4,339 by November 2, 2026, −6.9% a year. It held shares 41% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $18,507 (+5.5% a year), and held throughout $43,624 (+13.5%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Doyle William F | Director | 7 | −35.3% (7) | 0% | 0 | — | July 1, 2019 |
| Race Geoff | President | 0 | — | — | 5 | −35.1% (3) | May 2, 2023 |
| Kupfer David | Director | 3 | −21.2% (3) | 33% | 1 | — | December 3, 2021 |
| Luthringer Remy | CEO | 0 | — | — | 4 | −35.1% (3) | May 2, 2023 |
| Ahlholm Frederick W | SVP, CFO and Secretary | 0 | — | — | 3 | −63.3% (2) | May 2, 2023 |
| Care Capital Offshore Investments III LP | 10% owner | 0 | — | — | 3 | +4.9% (3) | March 20, 2015 |
| Index Venture Associates III Ltd | 10% owner | 0 | — | — | 3 | −53.1% (2) | June 21, 2019 |
| Index Venture Associates IV Ltd | 10% owner | 0 | — | — | 3 | +77.2% (3) | June 26, 2019 |
| Index Venture Associates V Ltd | 10% owner | 0 | — | — | 3 | −62.6% (1) | June 19, 2019 |
| Reilly Joseph H. | SVP & Chief Operating Officer | 0 | — | — | 3 | −35.1% (3) | December 17, 2019 |
| De Rubertis Francesco | Director | 1 | +5.9% (1) | 100% | 1 | −57.2% (1) | August 12, 2016 |
| Ollier Michele | Director | 1 | +5.9% (1) | 100% | 1 | −57.2% (1) | August 12, 2016 |
| Russell Richard E. | President | 0 | — | — | 2 | −56.5% (2) | December 13, 2019 |
| Van Heek G Jan | Director | 2 | −44.1% (1) | 0% | 0 | — | September 11, 2020 |
| Beer Marc D | Director | 1 | −30.8% (1) | 0% | 0 | — | March 21, 2017 |
| Hasler Hans Peter | Director | 1 | −44.1% (1) | 0% | 0 | — | June 27, 2019 |
| Johnson & Johnson | 10% owner | 1 | −11.2% (1) | 0% | 0 | — | March 17, 2015 |
When several insiders traded Minerva Neurosciences, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Minerva Neurosciences, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 2 buying crowds with six months of prices, it averaged +12.3% against the index. After 5 selling crowds, −18.4%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| May 31, 2023 | 3 selling | +29.0% | −11.8% | −85.3% |
| December 31, 2019 | 5 selling | +1.7% | −44.4% | −84.1% |
| July 31, 2019 | 4 buying | −36.1% | +10.0% | −56.6% |
| December 31, 2018 | 6 selling | +6.3% | −27.4% | −25.7% |
| December 29, 2017 | 3 selling | +11.0% | +34.4% | +18.8% |
| August 31, 2016 | 3 selling | +3.7% | −43.0% | −66.7% |
| March 31, 2015 | 4 buying | +15.8% | +14.6% | +21.1% |